Vertex Pharmaceuticals Logo

Email this page: News Release

Final Data from Phase 2 Combination Study of VX-809 and KALYDECO™ (ivacaftor) Showed Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation

For security reasons, registration is required before you can use this feature.
* Indicates required field